Aerie Pharmaceuticals’ (AERI) Buy Rating Reaffirmed at Cantor Fitzgerald
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI)‘s stock had its “buy” rating reissued by research analysts at Cantor Fitzgerald in a research note issued to investors on Wednesday. They presently have a $62.00 target price on the stock. Cantor Fitzgerald’s price target would suggest a potential upside of 12.01% from the stock’s current price.
AERI has been the subject of a number of other research reports. Zacks Investment Research downgraded Aerie Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. BidaskClub downgraded Aerie Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, June 17th. Canaccord Genuity reissued a “buy” rating and set a $65.00 target price on shares of Aerie Pharmaceuticals in a report on Monday, July 3rd. Mizuho reissued a “buy” rating and set a $70.00 target price on shares of Aerie Pharmaceuticals in a report on Wednesday, September 20th. Finally, Needham & Company LLC reissued a “buy” rating and set a $65.00 target price on shares of Aerie Pharmaceuticals in a report on Sunday, September 17th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and eleven have issued a buy rating to the stock. Aerie Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $66.62.
Aerie Pharmaceuticals (AERI) traded up 17.52% during trading on Wednesday, reaching $65.05. 2,143,608 shares of the company traded hands. The company’s market cap is $2.36 billion. Aerie Pharmaceuticals has a 12 month low of $32.05 and a 12 month high of $65.89. The company’s 50-day moving average is $54.52 and its 200 day moving average is $50.51.
COPYRIGHT VIOLATION WARNING: “Aerie Pharmaceuticals’ (AERI) Buy Rating Reaffirmed at Cantor Fitzgerald” was reported by American Banking News and is the property of of American Banking News. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/10/11/aerie-pharmaceuticals-aeri-buy-rating-reaffirmed-at-cantor-fitzgerald.html.
Institutional investors have recently bought and sold shares of the stock. Quantbot Technologies LP acquired a new position in shares of Aerie Pharmaceuticals in the first quarter worth approximately $107,000. Ameritas Investment Partners Inc. acquired a new position in Aerie Pharmaceuticals in the first quarter valued at approximately $108,000. BNP Paribas Arbitrage SA lifted its stake in Aerie Pharmaceuticals by 2,711.4% in the second quarter. BNP Paribas Arbitrage SA now owns 3,711 shares of the company’s stock valued at $195,000 after buying an additional 3,579 shares during the period. Amalgamated Bank acquired a new position in Aerie Pharmaceuticals in the second quarter valued at approximately $204,000. Finally, Palisade Capital Management LLC NJ acquired a new position in Aerie Pharmaceuticals in the second quarter valued at approximately $212,000. 94.64% of the stock is currently owned by institutional investors.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.